Abstract:Mutation profiling of circulating tumor DNA (ctDNA) and pleural effusion sediment containing tumor cells (ETCs) were commonly applied in clinical practice. Several studies suggested that tumor-derived DNA from pleural effusion supernatant (etDNA) might be a better candidate for detecting gene alterations in lung cancer. However, little is known regarding the abundance and diversity of tumor DNA acquired among different types of liquid biopsy. We performed targeted next generation sequencing (NGS)-based genetic profiling on tumor tissue, pleural effusion (etDNA & ETCs) and contemporaneous ctDNA from 63 lung cancer patients (58 adenocarcinoma, 2 adenosquamous carcinoma, 2 SCLC, 1 neuroendocrine carcinoma), among which 28 patients had paired tumor tissue samples. Genomic DNA from whole blood of each patient was used for germline control. Driver mutation and rearrangement profiling was validated using ARMS-PCR, FISH, or Ventana IHC assay in tumor tissue as golden standard. We identified tumor-specific mutations in 98%, 89%, 86%, and 100% of patients in their etDNAs, ETCs, ctDNAs and tumor tissues, respectively (p<0.01). etDNAs showed a significantly higher tumor-specific mutation number per patient (Median: 5) compared to ETCs and plasma ctDNAs (Median of 3 for both), while the median number in tumor tissues is 4 per patient. The detection sensitivity for EGFR mutations in etDNAs is 95%, higher than that in ETCs and ctDNAs (89% and 63%, respectively). Two patients detected ALK fusion in tumor tissue were also positive in etDNA, only one patient was positive in ETCs and ctDNA, respectively. A total of 298 genetic alterations, including point mutations, indels, copy number variations (CNVs) and gene fusions, were identified in etDNAs from all the patients. However, only 74% and 57% of these alterations were detected in contemporaneous ETCs and ctDNA samples, with CNVs having the lowest detection sensitivity as 49% and 11%, especially in lung cancer patients without extrathoracic metastasis, as none of the CNVs detected in etDNAs were captured in plasma ctDNAs of these patients. Furthermore, driver mutations and rearrangements in etDNA showed a strong correlation to targeted therapy efficacy. This study demonstrated that etDNA had significantly higher tumor-specific mutation detection rate and sensitivity compared to ETCs and ctDNA. etDNA from supernatant of pleural effusion is a promising source for genetic testing to guide treatment-decision making in lung cancer. This study is funded by Shanghai Science and Technology Program (15ZR1406400).

A study of pleural effusion in genomic detection of lung adenocarcinoma

Detection of EGFR Gene Mutation Status from Pleural Effusions and Other Body Fluid Specimens in Patients with Lung Adenocarcinoma

Liquid Biopsies Using Pleural Effusion-Derived Exosomal DNA in Advanced Lung Adenocarcinoma.

Molecular Profiling of Lung Adenocarcinoma Using Pleural Effusion Specimens.

Clinical significance of multi-sample next-generation sequencing for detection of gene mutations in non-small cell lung cancer

The study of detection EGFR gene mutation in non-small cell lung cancer tissue and matched pleural effusion

Comparisons of EGFR Mutation Status in Tumor Tissues, Pleural Effusion Cancer Cells and Cfdna Samples of Patients with Lung Adenocarcinoma

MA 20.13 Etdna: Tumor-Derived DNA from Pleural Effusion Supernatant As a Promising Source for NGS-Based Mutation Profiling in Lung Cancer

Comparison of Epidermal Growth Factor Receptor Gene Mutations Identified Using Pleural Effusion and Primary Tumor Tissue Samples in Non-Small Cell Lung Cancer.

A Multicenter Real-World Study of Tumor-Derived DNA from Pleural Effusion Supernatant in Genomic Profiling of Advanced Lung Cancer.

Application of Next Generation Sequencing in Pleural Effusion Molecular Profiling Using Oncomine™ Lung Cell-Free Total Nucleic Acid Research Assay.

Abstract 558: Muti-gene ARMS PCR Using Both Cfdna and Cfrnain the Supernatant of Pleural Effusion Achieves Rapid and Accuracy Driver Gene Mutations Detection

Prediction of Epidermal Growth Factor Receptor Mutations in the Plasma/pleural Effusion to Efficacy of Gefitinib Treatment in Advanced Non-Small Cell Lung Cancer.

Clinical value of the detection of EGFR gene mutations in pleural effusion cell blocks among patients with non-small-cell lung cancer

Gene Alterations in Paired Supernatants and Precipitates from Malignant Pleural Effusions of Non-Squamous Non-Small Cell Lung Cancer

Multigene PCR Using Both Cfdna and Cfrna in the Supernatant of Pleural Effusion Achieves Accurate and Rapid Detection of Mutations and Fusions of Driver Genes in Patients with Advanced NSCLC

[A Method for Isolating Tumor Cells from Large Volume of Malignant Pleural  Effusion and Its Efficacy Evaluation].

Comparative Study of EGFR Mutations Detected in Malignant Pleural Effusion, Plasma and Tumor Tissue in Patients with Adenocarcinoma of the Lung

Tumor-derived DNA from Pleural Effusion Supernatant As a Promising Alternative to Tumor Tissue in Genomic Profiling of Advanced Lung Cancer

Relationship Between Mutations of Epidermal Growth Factor Receptor in the Plasma and Pleural Effusion and Responses to Gefitinib in Advanced Pretreated Non-Small Cell Lung Cancer

Distinct Profile of Cell-Free DNA in Malignant Pleural Effusion of Non-Small Cell Lung Cancer and Its Impact on Clinical Genetic Testing.